Literature DB >> 17634882

Clinical outcome of stereotactic body radiotherapy of 54 Gy in nine fractions for patients with localized lung tumor using a custom-made immobilization system.

Masahiko Aoki1, Yoshinao Abe, Hidehiro Kondo, Yoshiomi Hatayama, Hideo Kawaguchi, Akira Fujimori, Katsumasa Suzaki, Morio Seino, Takeshi Morita, Makoto Souma, Takao Tsushima, Shingo Takanashi.   

Abstract

PURPOSE: The aim of this study was to investigate the clinical outcome of stereotactic body radiotherapy (SBRT) of 54 Gy in nine fractions for patients with localized lung tumor using a custom-made immobilization system. METHODS AND MATERIALS: The subjects were 19 patients who had localized lung tumor (11 primaries, 8 metastases) between May 2003 and October 2005. Treatment was conducted on 19 lung tumors by fixed multiple noncoplanar conformal beams with a standard linear accelerator. The isocentric dose was 54 Gy in nine fractions. The median overall treatment time was 15 days (range 11-22 days). All patients were immobilized by a thermo-shell and a custom-made headrest during the treatment.
RESULTS: The crude local tumor control rate was 95% during the follow-up of 9.4-39.5 (median 17.7) months. In-field recurrence was noted in only one patient at the last follow-up. The Kaplan-Meier overall survival rate at 2 years was 89.5%. Grade 1 radiation pneumonia and grade 1 radiation fibrosis were observed in 12 of the 19 patients. Treatment-related severe early and late complications were not observed in this series.
CONCLUSION: The stereotactic body radiotherapy of 54 Gy in nine fractions achieved acceptable tumor control without any severe complications. The results suggest that SBRT can be one of the alternatives for patients with localized lung tumors.

Entities:  

Mesh:

Year:  2007        PMID: 17634882     DOI: 10.1007/s11604-007-0141-7

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  18 in total

1.  A system for stereotactic radiosurgery with a linear accelerator.

Authors:  W Lutz; K R Winston; N Maleki
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-02       Impact factor: 7.038

2.  Clinical outcome of hypofractionated conventional conformation radiotherapy for patients with single and no more than three metastatic brain tumors, with noninvasive fixation of the skull without whole brain irradiation.

Authors:  Masahiko Aoki; Yoshinao Abe; Yoshiomi Hatayama; Hidehiro Kondo; Kiyoshi Basaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-03       Impact factor: 7.038

3.  Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience.

Authors:  M Uematsu; A Shioda; A Suda; T Fukui; Y Ozeki; Y Hama; J R Wong; S Kusano
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-11-01       Impact factor: 7.038

4.  The radiobiology of radiosurgery.

Authors:  D A Larson; J C Flickinger; J S Loeffler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-02-15       Impact factor: 7.038

5.  Four-dimensional treatment planning and fluoroscopic real-time tumor tracking radiotherapy for moving tumor.

Authors:  H Shirato; S Shimizu; K Kitamura; T Nishioka; K Kagei; S Hashimoto; H Aoyama; T Kunieda; N Shinohara; H Dosaka-Akita; K Miyasaka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-09-01       Impact factor: 7.038

6.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame.

Authors:  Yasushi Nagata; Kenji Takayama; Yukinori Matsuo; Yoshiki Norihisa; Takashi Mizowaki; Takashi Sakamoto; Masato Sakamoto; Michihide Mitsumori; Keiko Shibuya; Norio Araki; Shinsuke Yano; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-19       Impact factor: 7.038

7.  Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner.

Authors:  Hiroshi Onishi; Kengo Kuriyama; Takafumi Komiyama; Shiho Tanaka; Naoki Sano; Kan Marino; Satoshi Ikenaga; Tsutomu Araki; Minoru Uematsu
Journal:  Lung Cancer       Date:  2004-07       Impact factor: 5.705

8.  Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study.

Authors:  Hiroshi Onishi; Tsutomu Araki; Hiroki Shirato; Yasushi Nagata; Masahiro Hiraoka; Kotaro Gomi; Takashi Yamashita; Yuzuru Niibe; Katsuyuki Karasawa; Kazushige Hayakawa; Yoshihiro Takai; Tomoki Kimura; Yutaka Hirokawa; Atsuya Takeda; Atsushi Ouchi; Masato Hareyama; Masaki Kokubo; Ryusuke Hara; Jun Itami; Kazunari Yamada
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

9.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

10.  Stereotactic radiotherapy of malignancies in the abdomen. Methodological aspects.

Authors:  I Lax; H Blomgren; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1994       Impact factor: 4.089

View more
  6 in total

1.  A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927).

Authors:  Gregory M M Videtic; Chen Hu; Anurag K Singh; Joe Y Chang; William Parker; Kenneth R Olivier; Steven E Schild; Ritsuko Komaki; James J Urbanic; Robert D Timmerman; Hak Choy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-17       Impact factor: 7.038

2.  Radiation-induced rib fracture after stereotactic body radiotherapy with a total dose of 54-56 Gy given in 9-7 fractions for patients with peripheral lung tumor: impact of maximum dose and fraction size.

Authors:  Masahiko Aoki; Mariko Sato; Katsumi Hirose; Hiroyoshi Akimoto; Hideo Kawaguchi; Yoshiomi Hatayama; Shuichi Ono; Yoshihiro Takai
Journal:  Radiat Oncol       Date:  2015-04-22       Impact factor: 3.481

3.  Clinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors: a single institutional study with almost uniform dose with different five treatment schedules.

Authors:  Masahiko Aoki; Yoshiomi Hatayama; Hideo Kawaguchi; Katsumi Hirose; Mariko Sato; Hiroyoshi Akimoto; Ichitaro Fujioka; Shuichi Ono; Eiki Tsushima; Yoshihiro Takai
Journal:  Radiat Oncol       Date:  2016-01-20       Impact factor: 3.481

4.  Prognostic impact of average iodine density assessed by dual-energy spectral imaging for predicting lung tumor recurrence after stereotactic body radiotherapy.

Authors:  Masahiko Aoki; Katsumi Hirose; Mariko Sato; Hiroyoshi Akimoto; Hideo Kawaguchi; Yoshiomi Hatayama; Ichitaro Fujioka; Mitsuki Tanaka; Shuichi Ono; Yoshihiro Takai
Journal:  J Radiat Res       Date:  2016-01-28       Impact factor: 2.724

5.  Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study.

Authors:  Masahiko Aoki; Yoshiomi Hatayama; Hideo Kawaguchi; Katsumi Hirose; Mariko Sato; Hiroyoshi Akimoto; Hiroyuki Miura; Shuichi Ono; Yoshihiro Takai
Journal:  J Radiat Res       Date:  2015-10-22       Impact factor: 2.724

6.  Identification of novel prognostic factors focusing on clinical outcomes in patients with non-small cell lung cancer after stereotactic body radiotherapy.

Authors:  Hikari Sato; Fumiki Ito; Kazuki Hasegawa; Ryo Saga; Yoichiro Hosokawa; Mitsuki Tanaka; Masahiko Aoki
Journal:  Oncol Lett       Date:  2022-01-11       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.